EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock News

NASDAQ:EPRX - Nasdaq - CA29842P1053 - Common Stock - Currency: USD

5.41 +0.05 (+0.93%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EPRX Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Benzinga - Mentions: ESLT SRPT BRZE SGMT

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

15 days ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

a month ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

a month ago - By: Benzinga - Mentions: AMIX IROH JNPR FGI ...

Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

News Image

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

5 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

6 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces CFO Succession

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

10 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

10 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Strengthens Senior Management Team

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference